CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...

For Q1 2025, BlackLine projects revenue between $166M and $168M and non-GAAP operating margin of 16.5%-17.5%. Full-year 2025 revenue guidance stands at $699M to $705M, reflecting 7%-8% growth.

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...